Mivacurium

Summary

Mivacurium (CHEMBL1182833) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 9
• Chemistry: 1029.3 Da · C58H80N2O14+2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1182833
Name	Mivacurium
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5281042
Molecular formula	C58H80N2O14+2
Molecular weight	1029.3
InChIKey	ILVYCEVXHALBSC-OTBYEXOQSA-N

SMILES: C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C

IUPAC name: bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate

Also known as: BW B109OU, BW-B109OU, Mivacurium, Mivacurium cation, Mivacurium ion, SID50112723, mivacurium, SID144206462, MIVACURIUM, Mivacurium chloride

Parent form; salt/anhydrous children: CHEMBL984

Patent coverage: 9 distinct patent families (12 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 10 (83%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
Not specified	5
PHASE4	2
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01427985	PHASE4	COMPLETED	Influence of Premedication Protocols for Neonatal Endotracheal Intubation on Cerebral Oxygenation
NCT02117401	PHASE4	COMPLETED	A Prospective, Multi-center, Randomized Controlled Study of Muscle Relaxation Effect and Safety of Mivacurium Chloride in Pediatric Surgery Patients
NCT02473601	PHASE2	UNKNOWN	Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis
NCT01906528	PHASE1	COMPLETED	Sex-related Differences in the Response to the Muscle Relaxant Drug Mivacurium
NCT06709066	Not specified	NOT_YET_RECRUITING	Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy
NCT01966484	Not specified	COMPLETED	Low Dose Mivacurium vs. Low Dose Succinylcholine for Rigid Bronchoscopy
NCT02914119	Not specified	COMPLETED	Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals
NCT05558137	Not specified	COMPLETED	Mivacurium 0.2 mg/kg in Young (18 - 40 Years) and Elderly (= 80 Years) Patients
NCT06072534	Not specified	UNKNOWN	Evaluation of Effectiveness of Two Different Doses of Mivacurium in Rapid Sequence Intubation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 5 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).